De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection

Int Urol Nephrol. 2008;40(2):539-41. doi: 10.1007/s11255-007-9241-7.

Abstract

This paper describes the case of a patient with HCV, without previous evidence of nephropathy, who following two well-tolerated cycles of treatment with interferon alone developed nephrotic syndrome after a third attempt with ribavirin associated with peginterferon alfa 2b. The patient exhibited a total remission when the antiviral treatment was discontinued.

Publication types

  • Case Reports

MeSH terms

  • Alanine Transaminase / blood
  • Antiviral Agents / adverse effects*
  • Aspartate Aminotransferases / blood
  • Drug Therapy, Combination
  • Female
  • Hepatitis C, Chronic / blood
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects*
  • Middle Aged
  • Nephrotic Syndrome / chemically induced*
  • Polyethylene Glycols
  • Recombinant Proteins
  • Ribavirin / adverse effects*

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • peginterferon alfa-2b